Core Insights - Siemens Healthineers reported first-quarter operating profit that exceeded market expectations, driven by strong margin performance in its core imaging and cancer-care units [1] - The company experienced a decline in other areas, but the robust performance in its primary segments helped mitigate the overall impact [1] Financial Performance - The operating profit for the first quarter was notably higher than analysts' forecasts, indicating a positive trend in financial health [1] - The strong margins in imaging and cancer-care units suggest effective cost management and operational efficiency [1]

Core Insights - Boston Scientific achieved over $20 billion in sales for 2025, marking a mid-teens growth for the second consecutive year, driven by innovation and execution across business units [6][30] - The company reported a Q4 operational sales growth of 14% and organic sales growth of 13%, exceeding guidance [6][29] - Full year 2025 adjusted EPS grew 22% to $3.06, surpassing guidance, with operational sales growth of 19% and organic sales growth of 16% [7][30] Financial Performance - Q4 consolidated revenue reached $5.286 billion, representing a 15.9% reported growth, with operational revenue growth of 14.3% [29] - Full year 2025 consolidated revenue was $20.74 billion, a 19.9% increase, with operational revenue growth of 19.2% [30] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [31] Business Unit Highlights - The U.S. market saw a 17% growth in Q4 and 26% for the full year, particularly strong in EP, WATCHMAN, and ICTx [8] - The Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [14] - WATCHMAN business grew 29% in Q4, with strong adoption of concomitant procedures [22] Regional Performance - Europe, Middle East, and Africa (EMEA) grew 5% in Q4 and 3% for the full year, with high single-digit growth expected excluding the impact of product discontinuation [9] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, driven by strong performance in Japan and China [10][11] Future Outlook - For Q1 2026, the company expects organic growth of 8.5% to 10% and for the full year, guidance is set at 10% to 11% [8][36] - Adjusted EPS for 2026 is projected to be between $3.43 and $3.49, indicating a growth of 12% to 14% [38] - The company anticipates continued momentum in EP and WATCHMAN, with expectations for the market to grow approximately 15% in 2026 [26][72] Strategic Acquisitions - Boston Scientific announced agreements to acquire Penumbra and Valencia Technologies, expected to close in 2026, enhancing its portfolio in high-growth segments [15][35] - The acquisition of Nalu Medical has been completed, complementing the neuromodulation pain franchise [35]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted EPS for Q4 was $0.80, growing 15% year-over-year, exceeding guidance [19] - Full year 2025 adjusted EPS was $3.06, reflecting a 22% increase compared to 2024, marking the third consecutive year of 20%+ adjusted EPS growth [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved 8% organic growth in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% organically for the full year, with strong performance from the brain franchise [6] - Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth segments and expanding product offerings [24][25] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key areas [52][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to face challenges in the first half of 2026 due to product discontinuations but anticipates a stronger performance in the second half [46] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive future growth [63] Other Important Information - The company expects full-year 2026 adjusted gross margin to be in line with 2025, with a slight expansion in operating margin anticipated [21] - Free cash flow for 2025 was $3.659 billion, exceeding expectations, with a target of approximately $4.2 billion for 2026 [24] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that U.S. EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [34][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials on Watchman uptake, with robust growth continuing [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to be around 15%, with confidence in maintaining market leadership despite increased competition [44][51] Question: Diversification of growth drivers - Management emphasized ongoing investments in various business units, including Neuromodulation and Urology, to ensure consistent performance across the portfolio [60][62] Question: Confidence in long-term growth targets - Management reaffirmed confidence in achieving long-term revenue growth targets of 10%+, supported by strategic acquisitions and market leadership [86]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [18] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [19] - Adjusted EPS for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [18] - Full year 2025 adjusted EPS was $3.06, growing 22% versus 2024, also exceeding guidance [19] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [4] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [4] - Neuromodulation grew 10% in Q4 and delivered 8% organic growth for the full year, with strong performance from the brain franchise [5] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [6] - Watchman business grew 29% in Q4 and maintained strong double-digit growth for the full year [12] Market Data and Key Metrics Changes - U.S. operational growth was 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [2] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [3] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [2] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [3] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth markets and expanding product offerings [24][6] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key segments [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27] - The company expects to face challenges in the first half of 2026 due to product removals and market adjustments but anticipates stronger performance in the latter half [25][43] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive long-term growth [61] Other Important Information - The company reported free cash flow of $3,659 million for the full year 2025, exceeding expectations [22] - The legal reserve was $242 million as of December 31, with $46 million already funded [24] - The company maintains a strong balance sheet with cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9 times [23] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management reassured that Q4 results exceeded internal targets, with EP growing 35% and Watchman growing 29%, indicating strong market share gains [30][34] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [36][38] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [41][42] Question: Diversification of growth drivers - Management highlighted strong performance expected in Neuromod, Urology, and Endoscopy, with ongoing investments to ensure consistent growth across all business units [59][60]

Core Insights - The investment environment in 2025 was challenging, with foreign equity markets achieving their best returns in over a decade, while the International Growth Composite Portfolio finished the year essentially flat due to a market preference for cyclically sensitive businesses [8][11]. Portfolio Performance - The International Growth Composite Portfolio's performance was -2.21% for the quarter and 0.68% year-to-date, compared to the MSCI ACWI (ex-USA) which returned 5.05% for the quarter and 32.39% year-to-date [5]. - Top contributors to the Portfolio's performance included Tokyo Electron, ASML, and Shopify, while the largest detractors were Monday.com, MercadoLibre, and SAP [13][17]. Company-Specific Insights - **Tokyo Electron**: A leading player in semiconductor manufacturing equipment, expected to grow revenues at a high single-digit rate and increase operating margins from 25% in 2024 to 35% in the medium term, driving mid-teens earnings growth [14]. - **ASML**: Benefiting from investor optimism around AI, as its equipment is essential for advanced chips, which are critical for AI applications [16]. - **Monday.com**: Despite strong results, the stock sold off due to concerns over near-term growth slowdown, but revenue growth is expected to sustain over 20% as it expands its market reach [18]. - **MercadoLibre**: The largest e-commerce platform in Latin America, experiencing a decline in stock price due to a slight decrease in operating margin while investing in growth initiatives [19]. - **SAP**: Despite cloud revenue growth exceeding expectations, the stock faced pressure due to market conditions, but is viewed as resilient with a strong market position and high recurring revenues [20]. Portfolio Activity - New position established in **Nintendo**, which is expected to see significant growth following the release of the Switch 2, with anticipated earnings growth of 30% annually over the next few years [23]. - Positions in **Teleperformance** and **Siemens Healthineers** were eliminated due to ongoing business challenges, reallocating funds to invest in Nintendo and Tencent [25][26]. Market Outlook - The outlook for the Portfolio remains positive, with expectations of benefiting from structural trends such as technology shifts and growth in emerging markets like India [27].

Core Viewpoint - The article discusses the investment positions held by the author in specific companies, indicating a long position in SIEGY and SMMNY, which may suggest a positive outlook on these stocks [1]. Group 1 - The author has a beneficial long position in the shares of SIEGY and SMMNY, either through stock ownership, options, or other derivatives [1]. - The article expresses the author's personal opinions and is not receiving compensation for it, aside from Seeking Alpha [1]. Group 2 - The author emphasizes that the article may sound like financial advice but clarifies that it is not licensed to provide such advice [2]. - Investors are encouraged to conduct their own due diligence and research prior to making any investment decisions [2].

Core Insights - The artificial intelligence boom is gaining traction in the US and China, while Europe's role in AI markets may be undervalued, presenting new investment opportunities for 2026 [1] - AI's share of total European venture capital has increased to 27%, indicating a growing recognition of Europe's AI talent [1] Investment Landscape - The US has allocated 34% of its €1.33 trillion in VC funding to AI, while Europe has only allocated 18% of its €252 billion, highlighting a funding gap but also potential for growth in small-cap European AI stocks [2] - Concerns about a potential AI bubble in the US may lead investors to consider European stocks with calmer valuations and more resilient P/E ratios [3] Small-Cap European AI Stocks - **BE Semiconductor Industries (AMS: BESI)**: A major player in semiconductor manufacturing with a market cap of €12 billion, benefiting from high-end chip demand, particularly from Samsung [4][5] - **Indra Sistemas (BME: IDR)**: A Spanish defense firm expected to gain from AI integration and increased defense spending, with a stock rally of over 140% since early 2023 [6][7] - **STMicroelectronics (EPA: STMPA)**: A semiconductor stock with a market cap of €22 billion, recently secured a €1 billion deal to enhance competitiveness in AI [8][9] - **SUSS MicroTec (ETR: SMHN)**: The smallest on the list with a market cap of €850 million, specializing in lithography and microfabrication, has seen a stock increase of almost 190% since 2023 [10][11] - **Siemens Healthineers (OTC:SMMNY)**: A medical tech company with a market cap of around €52 billion, positioned to benefit from growing AI investments in healthcare [12][13] Market Outlook - European AI stocks present growth opportunities for investors seeking alternatives to high valuations in the US market, but thorough research is essential before investment [14] - Analysts are divided on the future of the AI industry, and any signs of strain in large-cap stocks could impact the growth of promising European companies [15]

Core Insights - Avanos Medical (AVNS) and Siemens Healthineers have entered a strategic co-marketing agreement to enhance outpatient and interventional pain management by integrating advanced imaging with radiofrequency ablation (RFA) technologies [2][10] - The partnership reflects a trend of shifting complex pain procedures from hospitals to outpatient settings, focusing on flexible and cost-efficient solutions that improve clinical outcomes [3][8] Company Collaboration - The collaboration combines AVNS' RFA expertise with Siemens Healthineers' imaging technologies, aiming to improve procedural precision and broaden access to outpatient pain management solutions [4][5] - Siemens Healthineers' mobile C-arm systems, such as Cios Select and Cios Flow, will enhance imaging performance and support operational efficiency in pain management procedures [5][6] Strategic Implications - The agreement allows both companies to leverage existing strengths, enhancing AVNS' RFA portfolio and extending Siemens Healthineers' mobile C-arm systems into outpatient specialties [7] - The initial focus on the U.S. market, along with joint education and marketing initiatives, suggests a strategy aimed at accelerating adoption of these technologies [8] Industry Context - The pain management sector is witnessing strategic innovations from major MedTech players like Teleflex, Stryker, and Baxter, each pursuing unique approaches to meet evolving clinical needs [9] - Teleflex focuses on regional anesthesia solutions to enhance procedural safety and efficiency, while Stryker emphasizes minimally invasive outpatient solutions for spinal conditions [11][12] - Baxter offers ready-to-use formulations for local or regional anesthesia, streamlining administration and enhancing procedural efficiency [13]

Core Viewpoint - The fourth quarter of 2025 experienced a sharp 5% sell-off followed by a quick recovery, with global stocks reaching all-time highs, influenced by concerns over a potential AI bubble and subsequent strong earnings from NVIDIA [4][5]. Portfolio Performance & Attribution - The Polen Global Growth Composite Portfolio returned -2.5% gross of fees and -2.7% net of fees in Q4 2025, underperforming the MSCI All Country World Index, which returned +3.3% [7]. - Top relative contributors included Eli Lilly, Alphabet, and Shopify, while Oracle, Paycom Software, and CoStar Group were the largest detractors [7][8]. - Eli Lilly's stock rallied over 40% in Q4 due to strong financial results and a favorable agreement on drug pricing, despite earlier concerns [8]. - Oracle's performance reversed from the previous quarter, primarily due to skepticism regarding its future revenue tied to OpenAI, impacting its stock negatively [9]. Portfolio Activity - New positions were initiated in Tencent Holdings and Spotify, while positions in Sage Group, Willis Towers Watson, ICON Plc, and Workday were eliminated to fund these investments [10][11]. - Tencent has shown consistent earnings growth of over 30% annually for the past three years, and its valuation is considered reasonable for sustainable revenue growth [11]. - Spotify is viewed as a leading streaming network with significant growth potential, expecting over 20% annual free cash flow growth for the next five years [12]. Outlook - The datacenter capital expenditure cycle is expected to continue, driven by increasing demand and supportive government policies, suggesting a favorable environment for growth in revenues and earnings for key players [17]. - The portfolio is positioned to deliver above-average earnings growth, with a focus on sectors outside of the AI and datacenter themes, ensuring resilience regardless of market drivers [18].

Core Insights - Siemens Healthineers emphasizes its leadership in AI and innovation, investing approximately €2 billion in R&D with a workforce of 13,000 dedicated to research and development [1][5] - The company focuses on non-communicable diseases, particularly cancer and cardiovascular diseases, advocating for early detection and personalized care [2] - Siemens Healthineers is recognized as a market leader in imaging and precision therapy, with a significant presence in 70 countries and an installed base of around 700,000 systems [3] R&D and Financial Strategy - The company prioritizes R&D investment and balance-sheet discipline, with a net debt/EBITDA ratio reduced from approximately 4x to 2.8x, targeting 2.5x [5][13] - Siemens Healthineers anticipates revenue growth of 5%-6% and adjusted EPS between €2.20 and €2.40 for the fiscal year, accounting for a combined €0.30 headwind from foreign exchange and tariffs [6][14] - The company aims to maintain a stable and growing dividend policy while considering selective share buybacks [13] Product and Market Development - Photon-counting CT is highlighted as a key growth driver, with cumulative orders reaching about €1.7 billion, representing roughly 30% of the CT business [7][9] - The PETNET radiopharmaceutical distribution business is projected to reach €1 billion in revenue soon, contributing to the company's procedure-based revenue stream [8][9] - Siemens Healthineers is expanding its imaging capabilities, including advancements in MRI and mammography, and is focused on molecular imaging applications [8] Guidance and Market Conditions - The company expects a "slightly weaker start" to the fiscal year due to diagnostics headwinds in China, primarily driven by price-based procurement [18] - Management anticipates flat development in China for the current year but projects a return to 5% growth in the midterm [17] - Siemens Healthineers is committed to returning to double-digit EPS growth starting in 2027, with plans to mitigate tariff impacts by 2028 [15]